Sarepta could be down on patient death in FDA database, says RBC Capital
RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that included am Elevidys patient death, which occurred in November in a patient ...
XPLR Infrastructure price target lowered to $12 from $15 at Scotiabank
Scotiabank lowered the firm’s price target on XPLR Infrastructure (NEP) to $12 from $15 and keeps a Sector Perform rating on the shares. The firm struggles to craft a bullish thesis for the company, ...